FDA approves Moderna's first mRNA-based flu vaccine

Published Aug 7, 09:33 PM UTC

Editorial responsibility

Prepared by: WorldAttention Editorial Systems
Human review: No named human review is recorded for this page.
Automated steps: Source reporting is collected, normalized, translated or condensed automatically when needed.
Page status: Automatically published source-backed update

How automation and AI are used · Report a correction or rights issue

The FDA has approved Moderna's new mRNA-based flu vaccine, marking the first mRNA flu shot to receive regulatory clearance. This vaccine, which uses the same technology as Moderna's COVID-19 vaccine, is designed to offer better protection against influenza, particularly for older adults who are more vulnerable to severe illness. The approval comes ahead of the upcoming flu season, and experts believe it could improve vaccine effectiveness and response times to circulating strains. The vaccine is expected to be available soon, with a focus on older populations. This development represents a significant milestone in influenza prevention, leveraging mRNA technology to potentially provide more robust and adaptable immunity compared to traditional flu vaccines.

Source

Part of this Story

FDA Approves Moderna's First mRNA Flu Vaccine for Older Adults

See the full Story: all sources and camp coverage

People and interests

FDA